The roadmap is final, please click here to read and download it.


innovation partnership for a roadmap on vaccines in europe

The “Innovation Partnership for a Roadmap on Vaccines in Europe” (IPROVE) - financed under the EU 7th Framework Programme (FP7) - aims to establish a clear vision of the priority innovations and technologies to boost research in the field of vaccine and vaccinology necessary to address infectious and non-infectious threats of importance to public health in Europe and beyond. Issues to be addressed will include inter-alia R&D needs to develop vaccines for the ageing population, emerging threats from hospital infections, high incidence of chronic diseases, low levels of prevention awareness and readiness, as well as the suboptimal use of existing cost-effective vaccines across different age groups.

The roadmap - expected to be finalised by December 2015 - will inform strategic decisions on the priorities for future vaccine investment in innovation and technological development at the level of the EU as well as of individual Member States.


The project will look at the entire vaccine innovation chain, from needs identification and conceptualisation to discovery and development, including interventions necessary to improve education curricula, and vaccine perception and awareness by the public. The project is considered key to strengthen Europe´s competitiveness and leading position in vaccinology, ensuring that also in the future Europe will maintain its leadership position and capacity to tackle unmet medical needs. Additional goals include favouring a more structured vaccine innovation agenda, tackling changing medical needs and supporting strained healthcare system budgets. Read more ...


The IPROVE consortium comprises four renowned organisations in the vaccine field in Europe: Vaccines Europe (VE), a specialised group within the European Federation of Pharmaceutical Industries and Associations (EFPIA) representing all major research-based vaccine global companies as well SMEs operating in Europe; the European Vaccine Initiative (EVI), a leading European Product Development Partnership supporting the development of effective, accessible, and affordable vaccines against diseases of poverty; the Sclavo Vaccines Association (SVA), a non-profit association whose main objective is to promote vaccine research targeted towards the discovery and study of advanced immunisation technologies; and EATRIS, a European consortium of 69 academic institutions of excellence in translational research, working together to advance candidates into clinical development. Read more ....

Latest News
iprove roadmap

Roadmap to bolster vaccine innovation launched in European Parliament

17 March, 2016

The “Innovation Partnership for a Roadmap on Vaccines in Europe” (IPROVE) - financed under the EU 7th Framework Programme (FP7) – today launched a strategy setting out a vision for vaccine research and innovation in Europe over the next 20 years.


Invitation: final summit IPROVE European roadmap on Vaccines

12 February, 2016

We would like to invite you on March 16th, 2016 for a European Parliament event to launch the strategic roadmap for future vaccine research in Europe.


IPROVE Roadmap Consultation: 24 Nov - 9 Dec 2015

25 November, 2015

The IPROVE roadmap draft is open for public consultation.
Click here to participate.

WHO Logo

World Immunization week (24 – 30 April)

29 April, 2015

WHO is calling for renewed efforts to get progress back on course ... read more

EURIPRED, call for TransNational access services open

9 Februari, 2015

EURIPRED is a EC-funded (FP7) infrastructure project for poverty related diseases, such as HIV, TB, malaria and hepatitis. The services provided by EURIRPED can be accessed for FREE by European scientists ... read more

IMI launches 115 million Euro calls

2 January, 2015

IMI launches 115 million Euro calls for proposals to develop vaccines and medicines of the future… read more

Launch of Ebola+, the IMI Programme on Ebola

7 November, 2014

IMI has launched an ambitious programme to accelerate the development of vaccines and treatments against Ebola and related diseases. The first Call under the Ebola+ programme has a total budget of €280m. ... read more

Ebola vaccine - available next year?

13 August, 2014

The World Health Organisation says Ebola is one of the most virulent viral diseases known to humankind, causing death in 50 to 90 percent of all clinically ill cases ... read more

New market research report available - International Antiviral Therapeutics Report 2014

11 August, 2014

This report reviews the current state-of-art of antiviral approaches including vaccines, pharmaceuticals and innovative technologies for delivery of therapeutics. ... read more